Medicare beneficiaries can receive acupuncture to treat lower back pain after CMS finalized coverage on Jan. 21. The treatment was previously non-covered by Medicare and was reviewed by CMS with evidence and examinations of policies of private payers.

Civica Rx and the Blue Cross Blue Shield Association and 18 of its health plans have teamed up to create a new subsidiary that will target low-cost generic drugs.

The world could soon have a new most expensive drug if an experimental gene therapy for hemophilia patients could come in with a price tag between $2 million and $3 million is approved.

For 2020, CVS Health has laid out a number of trends in the industry and several challenges to address, including chronic kidney disease care, social determinants of health, poverty and lack of healthcare access, and consumer preferences and engagement.

Civica Rx, the startup drug company founded by health foundations, is teaming up with Thermo Fisher Scientific in a seven-year agreement to develop and manufacture medications, with Civica serving as the owner of the regulatory pathway.

A lower percentage of physicians reported they were burned out in a recent survey compared to five years ago.

The innovation and venture capital arm of University of Pittsburgh Medical Center (UPMC) is planning to invest $1 billion into life sciences to develop new drugs, diagnostics and devices over the next four years.

CVS Health is on track to expand its HealthHub store concept to more than 600 locations in 2020, the company revealed during a presentation at the J.P. Morgan Healthcare Conference in San Francisco.

Global healthcare company Cigna has partnered with New York-based health insurance startup Oscar Health to provide commercial health options to small businesses.

Mayo Clinic, the Rochester, Minn.-based nonprofit healthcare organization, has launched the Clinical Data Analytics Platform that will use deidentified data and scientific literature to improve patient health.

New medical treatments such as gene therapies come with a high price tag up to six figures, and drugmakers are working hard to ensure they can get reimbursed for these medicines in creative ways.

Cancer death rates achieved their largest one-year drop between 2016 and 2017, according to the latest data from the American Cancer Society, which published the findings in their journal.